To assess whether the reduction of NKG2A expression on the surface of CAR33-NK cells, which mostly maintained their activated and mature state (Figs. 2, 3), would lead to increased cytotoxic capacity of CAR33-KLRC1ko-NK cells, we analyzed their killing capacity against HLA-E and CD33 expressing AML cells, such as the AML cell line OCI-AML2 and patient-derived primary blast cells (Supplementary Fig. S4a and S5). This evidence concerns the gene CD33 and acute myeloid leukemia.